Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Melasma Revisited: Neurovascular Pathways, New Treatments, and Personalized Management
Description
The talk reframes melasma as a chronic neurovascular, inflammatory, and barrier-related pigmentary disorder rather than simple hyperpigmentation. The speakers review how melasma is especially burdensome in skin of color, often recurs because standard care overemphasizes hydroquinone and underaddresses vascular, inflammatory, hormonal, environmental, and visible-light triggers. They describe clinical variants, important differentials, and newer sites such as extra-facial melasma, emphasizing that erythema and telangiectasia support a vascular component. Management should be layered and long-term: assess subtype and triggers, prioritize camouflage and photoprotection with broad-spectrum sunscreen plus iron oxides, use triple-combination therapy for induction when appropriate, then transition to non-hydroquinone maintenance options. Newer topicals include mequinol, thiamidol, melisil, cysteamine, tranexamic acid, niacinamide, azelaic acid, and antioxidants, with advanced delivery systems like liposomes and nanotechnology. Oral tranexamic acid is highlighted for selected patients, with thrombotic screening and awareness of relapse risk. The talk also emphasizes patient education, compliance, and preconditioning before procedures to reduce PIH. Finally, it looks to the future: AI, biomarkers, imaging, and remote monitoring will enable more precise, personalized prediction, prevention, and management of melasma.
View moreConclusions
- Melasma should be understood as a chronic neurovascular-inflammatory-barrier disorder rather than a purely pigmentary problem.
- Treatment fails often because standard hydroquinone-focused regimens do not adequately address vascular, inflammatory, environmental, and hormonal drivers of disease.
- Patients with skin of color carry a higher disease burden and require greater attention to evidence-based, individualized management.
- Visible light, especially blue light, is a major relapse trigger in darker skin, making iron-oxide-containing photoprotection essential.
- The vascular component of melasma appears clinically important, supporting the use of tranexamic acid and vascular-targeted lasers in selected patients.
- Chronic low-grade inflammation and barrier dysfunction help sustain pigment persistence and justify anti-inflammatory and barrier-supportive strategies.
- The triple-combination regimen remains effective, but its limitations include relapse after stopping, insufficient action on non-pigment pathways, and risk of ochronosis with prolonged use.
- Next-generation non-hydroquinone topicals such as mequinol, thiamidol, cysteamine, azelaic acid, niacinamide, and tranexamic acid are becoming important maintenance alternatives.
- Oral tranexamic acid can benefit selected patients, but it requires thrombotic risk screening and still does not eliminate recurrence risk.
- Melasma management should be layered and long term, combining photoprotection, topicals, systemic therapy when needed, procedures, camouflage, and ongoing maintenance.
- Preconditioning and caution are necessary for procedures in skin of color to reduce the risk of post-inflammatory hyperpigmentation.
- Modern camouflage and skin-tint products are becoming part of therapy because they can provide coverage, photoprotection, and adjunctive anti-inflammatory or anti-pigment benefits.
- The future of melasma care lies in prediction, prevention, and personalization rather than simple suppression of pigmentation.
- AI, biomarkers, and multimodal imaging may transform melasma into a more measurable disease and improve relapse prediction and treatment selection.
- Daroach M, Vinay K, Bishnoi A, Parsad D, Kumaran MS. Extrafacial Melasma: A Scenario Less Explored. Indian Dermatol Online J. 2022 Jun 24;13(4):484-486.
- Moon HR, Jo SY, Kim HT, Lee WJ, Won CH, Lee MW, Choi JH, Chang SE. Loratadine, an H1 antihistamine, Inhibits Melanogenesis in Human Melanocytes. Biomed Res Int. 2019 Mar 17;2019:5971546.
- Liao T, Luo R, Deng Y, Yang H, Du Y. Targeting Melasma: Innovations in Pigment Deposition and Photoaging in Cosmetic Dermatology. J Cosmet Dermatol. 2026 Jan;25(1)#10.1111/jocd.70665